Heron Therapeutics | HRTX - Selling And Administration Expenses

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $23.34M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amarin USD 17.94M 17.86M Sep/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Insmed USD 186.38M 109.94M Sep/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.8M 14.6M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Surmodics USD 14.58M 2.05M Sep/2024
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Veracyte USD 51.73M 5.91M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025